$680 Million in Daily Turnover Crowns Terns as Most Active Stock Ahead of Merck Deal

Market Snapshot

Terns Pharmaceuticals Inc. shares, trading under the ticker TERN, posted a marginal intraday gain of 0.08% on April 8, 2026, closing at approximately $52.70 per share. Despite the stock's stability in price, trading activity exhibited a dramatic contraction in liquidity, with total turnover volume plummeting by 55.78% to $680 million compared to the previous session. This significant reduction in daily volume, which nonetheless ranked as the highest turnover among all stocks traded that day, reflects the market's consensus that the stock's price trajectory is now almost entirely tethered to the finalization of the pending acquisition. As the closing date for the deal approaches, the share price has effectively converged toward the acquisition premium, rendering daily volatility negligible and trading volume sparse as investors wait for the transaction to settle.

Key Drivers

The primary catalyst for Terns' market activity and investor sentiment remains the definitive agreement to acquire the biotech firm by pharmaceutical giant Merck & Co. for $53 per share in cash, representing a total equity value of approximately $6.7 billion. This premium of 42% over Terns' 90-day volume-weighted average price has effectively established a floor for the stock, limiting downside risk and suppressing the volatility typically associated with smaller biotechnology companies. The deal, which was publicly announced in late March, is driven by Merck's strategic imperative to bolster its oncology pipeline in anticipation of patent cliffs facing its blockbuster cancer drug, Keytruda, set to expire in 2028. Analysts from William Blair have indicated that the transaction is expected to close later this quarter, further solidifying the expectation that the acquisition will proceed without significant disruption.

A critical factor influencing the final terms of the merger was the release of updated clinical data regarding Terns' lead asset, TERN-701, an oral tyrosine kinase inhibitor currently in Phase 1 testing for chronic myeloid leukemia. During the due diligence phase, Terns provided Merck and a competing bidder with revised results from the CARDINAL study, which showed a lower major molecular response (MMR) achievement rate compared to the 64% rate disclosed in December 2025. This data update prompted a reassessment of the drug's potential, causing the competing unnamed bidder to withdraw from the process entirely, citing that the asset was no longer viewed as sufficiently differentiated or de-risked. The withdrawal of this rival suitor removed the threat of a higher counter-proposal, allowing Merck to negotiate the final price down from an initial offer of $61 per share.

The negotiation dynamics were further complicated by the specific clinical nuances of TERN-701's performance against existing therapies. The updated data suggested that the MMR rate was lower potentially due to a higher proportion of patients in the evaluable population having been pre-treated with asciminib, a Novartis drug. While Merck initially lowered its offer to $50 per share following these disclosures, Terns management successfully negotiated the price back up to the final $53 per share. Merck's SEC filings noted that despite the lower response rate, the data remained compelling relative to asciminib, and the company maintained enthusiasm for the transaction, viewing the asset as a potential challenger to Novartis' Scemblix, which generated over $1.28 billion in revenue last year.

Market analysts remain divided on the valuation of the deal, though the prevailing sentiment leans toward the acquisition being a strategic necessity for Merck rather than a bargain. Leerink Partners noted in a Tuesday evening note that the deal price may still underestimate the long-term potential of TERN-701, projecting sales to reach blockbuster levels by 2032 and global revenues of around $6.2 billion by 2040. However, Terns' own board acknowledged the impact of the new data, lowering their peak sales forecasts by 8% after the competing bidder's withdrawal. Despite these internal adjustments, the consensus among analysts is that the emergence of a higher bidder is now unlikely, and the focus has shifted entirely to regulatory approvals and the final closing of the transaction.

The convergence of the stock price near the $53 offer price and the sharp decline in trading volume underscores the market's confidence in the deal's completion. With the acquisition premium well-established and the competitive bidding process concluded, the stock has effectively transitioned into an arbitrage play where the primary variable is the timing of the closing rather than the likelihood of the deal itself. Investors are now positioned to receive the cash consideration upon the transaction's closure, expected in early May, with little incentive to hold the stock for further appreciation unless the final deal terms are revised unexpectedly.